{"title":"Adjunctive long-term use of Mucinex® leading to improvement in stable chronic bronchitis and patient’s quality of life: A case report","authors":"Selwyn Spangenthal , Connie Divel , Oktawia Borecka , Samuel Llewellyn","doi":"10.1016/j.hmedic.2025.100384","DOIUrl":null,"url":null,"abstract":"<div><div>We describe a case of a chronic obstructive pulmonary disease patient with stable chronic bronchitis who experienced improved quality of life and reduced symptoms during daily long-term Mucinex® (extended-release guaifenesin) use. Through a validated patient-reported outcome, the cough and sputum assessment questionnaire (CASA-Q), cough impact and symptoms scores showed improvements of 37.5 and 50 points, respectively, at week 11 compared to baseline. Similarly, sputum impact and symptoms scores improved by 37.5 and 41.7 points. While these observations support a potential benefit of adjunctive mucoactive therapy in chronic respiratory conditions, they should be interpreted cautiously and considered hypothesis-generating, highlighting the need for further controlled studies.</div></div>","PeriodicalId":100908,"journal":{"name":"Medical Reports","volume":"14 ","pages":"Article 100384"},"PeriodicalIF":0.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949918625002293","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
We describe a case of a chronic obstructive pulmonary disease patient with stable chronic bronchitis who experienced improved quality of life and reduced symptoms during daily long-term Mucinex® (extended-release guaifenesin) use. Through a validated patient-reported outcome, the cough and sputum assessment questionnaire (CASA-Q), cough impact and symptoms scores showed improvements of 37.5 and 50 points, respectively, at week 11 compared to baseline. Similarly, sputum impact and symptoms scores improved by 37.5 and 41.7 points. While these observations support a potential benefit of adjunctive mucoactive therapy in chronic respiratory conditions, they should be interpreted cautiously and considered hypothesis-generating, highlighting the need for further controlled studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
